Shares of Cipla are set to be in focus on Friday after the company received final approval from the U.S. Food and Drug Administration for its New Drug Application (NDA) for Nilotinib capsules ...

India's Cipla beats Q3 profit view as strong domestic ... joint venture with Nestle India and Nicotinell acquisition, the company said on Tuesday. India's Dr Reddy's Q2 profit drops on acquisition ...

Earnings Per Share (TTM) A company's net income for the trailing twelve month period expressed as a dollar amount per fully diluted shares outstanding. Market Capitalization Reflects the total ...

Umang Vohra to Nimura: "In the case of tariff barriers, generics companies are likely to be more selective, focusing on high-value opportunities including 'first to file'." The Managing Director ...

India, often dubbed the "pharmacy of the world", is among the top exporters to the U.S., especially for cheaper versions of ...

Discover the Cipla Stock Liveblog, your ultimate resource for real-time updates and insightful analysis on a prominent stock.

Cipla Limited is an Indian multinational pharmaceutical company that is headquartered in Mumbai, Maharashtra. The company is primarily known for producing generic drugs for various therapeutic uses.

According to Cipla, the regulatory clearance serves as an important landmark in the Company's journey, allowing it to expand the depth of its oncology portfolio and its foothold in the US market ...

According to Cipla, the regulatory clearance serves as an important landmark in the Company's journey, allowing it to expand the depth of its oncology portfolio and its foothold in the US market ...

NEW DELHI: Indian Pharmaceutical company Cipla has offered to manufacture an antiviral drug for bird flu called Zanamivir (Relenza) that is currently being manufactured by Glaxo Smithkline.

The Company advises the users to check with duly registered and qualified advisors before taking any investment decision. The Company does not guarantee the accuracy, adequacy or completeness of ...